EC Number   |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
|---|
   2.3.1.122 | Vaccinia |
26478198 |
Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A. |
therapeutic application
unassigned |
4
0 |
| 2.3.1.122 | Vaccinia |
27960596 |
Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection. |
unassigned |
0 |
| 2.3.1.122 | Vaccinia |
28633702 |
Impact of isoniazid preventive therapy on the evaluation of long-term effectiveness of infant MVA85A vaccination. |
ongoing research
therapeutic application
unassigned |
2
1
0 |
| 2.3.1.122 | Vaccinia |
28775896 |
Comprehensive definition of human immunodominant CD8 antigens in tuberculosis. |
therapeutic application
unassigned |
3
0 |
| 2.3.1.122 | Vaccinia |
30687792 |
Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A. |
ongoing research
therapeutic application
unassigned |
3
2
0 |
| 2.3.1.122 | Vaccinia |
31038197 |
MVA85A vaccine to enhance BCG for preventing tuberculosis. |
unassigned |
0 |
| 2.3.1.122 | Vaccinia |
33072631 |
IL-12 DNA Displays Efficient Adjuvant Effects Improving Immunogenicity of Ag85A in DNA Prime/MVA Boost Immunizations. |
causal interaction
therapeutic application
unassigned |
3
4
0 |
| 2.3.1.122 | Vaccinia |
33549390 |
Using an effective TB vaccination regimen to identify immune responses associated with protection in the murine model. |
therapeutic application
unassigned |
3
0 |
| 2.3.1.122 | Vaccinia |
33632562 |
Intranasal boosting with MVA encoding secreted mycobacterial proteins Ag85A and ESAT-6 generates strong pulmonary immune responses and protection against M. tuberculosis in mice given BCG as neonates. |
diagnostic usage
ongoing research
therapeutic application
unassigned |
1
1
2
0 |
| 2.3.1.122 | Vesicular Stomatitis |
18388911 |
Heterologous boosting of recombinant adenoviral prime immunization with a novel vesicular stomatitis virus-vectored tuberculosis vaccine. |
ongoing research
therapeutic application
unassigned |
3
3
0 |
